



A. Menarini Diagnostics, a division of the Menarini Pharmaceutical Industries Group, is proud to announce that the **GlucoDay®** system has obtained a CE mark under the Medical Device Directive – a major step forward in marketing the system in Europe.

GlucoDay® is an innovative professional use system for continuous subcutaneous glucose monitoring, utilizing the revolutionary microdialysis technique. It is the first system of its kind in the world to obtain the **MDD-CE** mark, achieving this goal before many other major multinational companies working on competing projects.

The system, a product of the research and development of **A. Menarini Diagnostics**, will be introduced onto the market by the end of this year and is covered by five separate patents.

GlucoDay's® dimensions are similar to that of a Walkman and it uses a microfibre no thicker than a human hair for dialysis. The physician inserts the microfibre under the skin in the abdominal region of the patient. The instrument remains activated for 48 hours and is worn in a portable pouch around the patient's waist.

During the test the patient can leave the doctor's office or outpatient department and carry out normal daily activities.

When the monitoring period has been completed, the patient returns to the doctor's office or outpatient department where the data recorded by the system during the previous 48 hours on the patients glucose level is transmitted to the physician's personal computer. This can be done through an infrared port without the use of any cables or connectors.

The computer can then visualize and analyze the glucose concentration trends over the 48-hour period, including the nocturnal hours when a hypoglycemic event can be particularly dangerous if not noticed, or if noticed late by the patient.

Based on the needs of the physician, **GlucoDay®** allows for the monitoring of subcutaneous glucose concentrations in real time.

Besides numerous other applications, **GlucoDay®** also allows clinicians to verify and adjust the patient's daily insulin therapy based on complete information which has never before been available to the diabetologist.

Expectations from the scientific world are high for **GlucoDay®** after the data of the multicentric studies performed and concluded with complete success in Italy was presented at recent scientific meetings. These studies included the participation of seven of the most important diabetology centers in Italy.

Two scientific papers on **GlucoDay®** will shortly be published in renowned international journals, "**Diabetes Care**" and "**Biosensor & Bioelectronics.**" The system was officially presented at the international level during the **European Congress of Diabetology** (EASD) held in Glasgow from September 9 to 13, 2001, where it caused great interest among the diabetes specialists present.

GlucoDay®, the pride and fruit of Italian research, represents a major step forward for improvement in the lives of the many patients affected by diabetes, a chronic disease whose prevalence is increasing rapidly throughout the world.

A. Menarini Diagnostics, the Italian company in the *in vitro* diagnostic market with the greatest international reach (affiliates in ten European countries), has a headcount of about 700 employees, with a projected turnover in 2001 equal to Euro 165 million, most of which (about 70%) is generated outside of Italy. Among the four strategic areas of the Division (Diabetes, Clinical Chemistry, Hematology, Immunology Tests), the greatest effort is concentrated on the Diabetes area.

Menarini Group is the largest Italian international pharmaceutical company and among the top 20 in Europe, with a turnover of over Euro 1,500 million. Active in the major therapeutic areas, the Group is composed of over 8,500 employees throughout the world, with affiliates in 170 countries.

For information: glucoday@menarini.it